(110 days)
No
The document describes a physical medical device (interbody fusion cage) and its materials and testing. There is no mention of software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
Explanation: The device is indicated for intervertebral body fusion in patients with degenerative disc disease, which is a therapeutic intervention aimed at treating a medical condition.
No
The device, Velofix™ PEEK Cervical Cage and Velofix™ PEEK Lumbar Cage, is an intervertebral body fusion cage intended for treatment of degenerative disc disease by facilitating fusion, not for diagnosing it.
No
The device description clearly states it is an "Interbody Fusion System" consisting of implants made of PEEK and tantalum, and implanted using stainless steel instruments. This indicates a physical medical device, not software.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly describes a surgical implant for spinal fusion. It is used in the body to treat a physical condition (degenerative disc disease).
- Device Description: The description details a physical implant made of PEEK and tantalum, designed to be placed between vertebrae.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (like blood, urine, or tissue) in vitro (outside the body) to provide information about a physiological state, health, or disease.
IVD devices are used for diagnostic purposes by analyzing samples outside the body. This device is a therapeutic implant used directly within the body.
N/A
Intended Use / Indications for Use
The Velofix™ PEEK Cervical Cage is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level from the C2-C3 disc to the C7-T1 disc. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion. Patients should have at least six weeks of non-operative treatment prior to treatment with an intervertebral cage.
The Velofix™ PEEK Lumbar Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease(DDD) at one or two levels for L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as back pain of discongenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended to be used with supplemental fixation.
Product codes
ODP, MAX
Device Description
The Velofix™ Interbody Fusion System(K132926) consists of implants available in various heights, width and angle with an open architecture to accept packing of autogenous bone graft and consist of:
-
- Cervical Interbody Fusion Device (Velofix™ PEEK Cervical Cage), which may be implanted as a single device via an anterior approach.
-
- Lumbar Interbody Fusion Device (Velofix™ PEEK Lumbar Cage), which may be implanted.
- Bilaterally via a posterior(PLIF) approach; o
- o As a single device via a transforaminal(TLIF) approach;
The Velofix™ Interbody Fusion System(Pending:K140864) contains additional sizes in PEEK Lumbar cages of The Velofix™ Interbody Fusion System(Cleared:
The implants are made of radiolucent polymer polyether-ether-ketone(PEEK-OPTIMA LT 1, ASTM F2026) body with the x-ray markers made of tantalum markers (ASTM F560). The Velofix " PEEK Lumbar Cage is implanted by using the instruments manufactured from stainless steel materials that conform to ASTM F899.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Cervical spine from C2-C3 disc to C7-T1 disc.
Lumbar spine from L2 to S1.
Indicated Patient Age Range
Skeletally mature patients.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The additional size of Velofix™ Interbody Fusion System was tested in a non clinical setting (bench testing) to assess that to no new safety and efficiency issues were raised with this device. The testing met all acceptance criteria and verifies that performance of the The additional size of Velofix™ Interbody Fusion System is substantially equivalent to predicate devices.
The following tests were performed:
- (1) Static compression test according to ASTM F2077
- (2) Dynamic compression test according to ASTM F2077
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Velofix™ Interbody Fusion System(K132926), Galaxy PLIF PEEK Cage (K122872), Capstone Spinal System (K082342)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
5. 510(k) Summary
JUL 2 2 2014
| Manufacturer: | U & I Corporation
20, Sandan-ro 76beon-gil(Rd), Uijeongbu-si, Gyeonggi-do,
Korea, 480-859 |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------|
| Sponsor: | U & I Corporation
20, Sandan-ro 76beon-gil(Rd), Uijeongbu-si, Gyeonggi-do,
Korea, 480-859 |
| Sponsor Contact: | Ji Yea Lee, Regulatory Affairs Assistant
+82 31 852 0102 (ext.632)
jylee@youic.com |
| Date Prepared: | April 01, 2014 |
| Device Name: | Trade Name: Velofix™ Interbody Fusion System |
| Classification Name: | Spinal Intervertebral Body Fusion Device, Cervical
Spinal Intervertebral Body Fusion Device, Lumbar
, per 21 CFR 888.3080 |
| Common Name: | Intervertebral Body Fusion Device, IBF Device |
| Product Code: | ODP, MAX |
| Predicate Devices: | Velofix™ Interbody Fusion System(K132926)
Galaxy PLIF PEEK Cage (K122872)
Capstone Spinal System (K082342) |
Description of Device:
The Velofix™ Interbody Fusion System(K132926) consists of implants available in various heights, width and angle with an open architecture to accept packing of autogenous bone graft and consist of:
-
- Cervical Interbody Fusion Device (Velofix™ PEEK Cervical Cage), which may be implanted as a single device via an anterior approach.
-
- Lumbar Interbody Fusion Device (Velofix™ PEEK Lumbar Cage), which may be implanted.
- Bilaterally via a posterior(PLIF) approach; o
- o As a single device via a transforaminal(TLIF) approach;
The Velofix™ Interbody Fusion System(Pending:K140864) contains additional sizes in PEEK Lumbar cages of The Velofix™ Interbody Fusion System(Cleared:
Velofix™ Interbody Fusion System
Image /page/0/Picture/13 description: The image shows the logo for USI Corporation. The logo consists of the letters "U" and "S" stacked on top of each other, with the letter "I" to the right. To the right of the letters is the word "CORPORATION" in a bold, sans-serif font. The logo is black and white.
1
K132926).
The implants are made of radiolucent polymer polyether-ether-ketone(PEEK-OPTIMA LT 1, ASTM F2026) body with the x-ray markers made of tantalum markers (ASTM F560). The Velofix " PEEK Lumbar Cage is implanted by using the instruments manufactured from stainless steel materials that conform to ASTM F899.
Intended Use:
The Velofix™ PEEK Cervical Cage is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level from the C2-C3 disc to the C7-T1 disc. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion. Patients should have at least six weeks of non-operative treatment prior to treatment with an intervertebral cage.
The Velofix™ PEEK Lumbar Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease(DDD) at one or two levels for L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as back pain of discongenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended to be used with supplemental fixation.
Substantial Equivalence:
The additional size of Velofix™ Interbody Fusion System is substantially equivalent to Velofix™ Interbody Fusion System(Cleared:K132926), Galaxy PLIF PEEK Cage (K122872), and Capstone Spinal System (K082342) in design, material, mechanical performance, function and intended use.
The mechanical performance of The additional size of Velofix™ Interbody Fusion System met the acceptance criteria which have been established from the predicate devices.
- Comparison Technological Characteristics
The predicate and proposed devices have the similar intended use and basic fundamental scientific technology and share the following similarities;
Velofix™ Interbody Fusion System
CORPORATION
2
- The similar indications for use .
- Similar design features .
- Incorporate the same or similar materials ●
- The equivalent mechanical performance
2. Performance Testing
The additional size of Velofix™ Interbody Fusion System was tested in a non clinical setting (bench testing) to assess that to no new safety and efficiency issues were raised with this device. The testing met all acceptance criteria and verifies that performance of the The additional size of Velofix™ Interbody Fusion System is substantially equivalent to predicate devices.
The following tests were performed:
- (1) Static compression test according to ASTM F2077
- (2) Dynamic compression test according to ASTM F2077
- Conclusion
The data and information provided in this submission support the conclusion that the Velofix™ Interbody Fusion System(K140864) is substantially equivalent to predicate devices with respect to indications for use and technological characteristics.
Velofix™ Interbody Fusion System
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES (USA)" around the perimeter. Inside the circle is a stylized symbol resembling a caduceus, with three wavy lines intersecting a staff-like element.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G699 Silver Spring, MD 20993-0002
July 22, 2014
U & I Corporation Ms. Ji Yea Lec Regulatory Affairs Assistant 20. Sandan-ro. 76beon-gil (Rd) Uijeongbu-si, Gyeonggi-do Republic of Korea 480-859
Re: K140864
Trade/Device Name: Velofix™ Interbody Fusion System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: ODP, MAX Dated: April 22. 2014 Received: April 28, 2014
Dear Ms. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (sec above) into either class 11 (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807): labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) {21 CFR 803}; good manufacturing practice requirements as set forth in
4
Page 2 - Ms. Ji Yca Lec
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevicesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincercly yours,
Ronald P. Jean -S for
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known) K140864
Device Name
VelofixTM Interbody Fusion System
Indications for Use (Describe)
The VelofixTM PEEK Cervical Cage is intervertebral body fusion in skeletally mature patients with decenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level from the C2-C3 disc to the C7-T1 disc. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion. Patients should have at least six weeks of non-operative treatment with an intervertebral cage.
The VelofixTM PEEK Lumbar Cage is indicated for use with autogenous bone graft in patients with degeneralive disc disease(DD) at one or two levels for 1,2 to Sh. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as back pain of discongenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended to be used with supplemental fixation.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
Katherine D. Kavlock, PhD
Division of Orthopedi
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the fire to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
*An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
SC Publiating Services (30) | 417-6749 EF